LNG‐IUS may leads to lower hysterectomy; histologically and non‐histologically indicated compared with non‐intrauterine progestogen (low certainty).
It is very uncertain whether LNG‐IUS changes adverse effects associated with hormones:Bleeding/spotting Nausea… compared with non‐intrauterine progestogen (very low certainty).
LNG‐IUS showed no clear difference in withdrawal secondary to adverse effects compared with non‐intrauterine progestogen (low certainty).
It is very uncertain whether LNG‐IUS changes satisfaction with treatment compared with non‐intrauterine progestogen (very low certainty).
Surgery showed no clear difference in satisfaction rate: surgery versus LNG‐IUS Endometrial ablation… compared with LNG‐IUS (low certainty).
Surgery probably leads to lower proportion of women with adverse events Endometrial ablation versus… compared with LNG‐IUS (moderate certainty).
Surgery probably leads to higher objective control of bleeding: menstrual loss under 80 ml per cycle… compared with LNG‐IUS (moderate certainty).
Surgery may leads to higher subjective control of bleeding: PBAC no more than 75 per cycle… compared with LNG‐IUS (low certainty).
Surgery showed no clear difference in satisfaction rate: surgery versus LNG‐IUS Endometrial ablation… compared with LNG‐IUS (low certainty).
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial polyps compared with endometrial surveillance alone (moderate certainty).
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial hyperplasia compared with endometrial surveillance alone (moderate certainty).
The LNG‐IUS with endometrial surveillance showed no clear difference in fibroids compared with endometrial surveillance alone (moderate certainty).
The LNG‐IUS with endometrial surveillance probably leads to higher abnormal vaginal bleeding or spotting compared with endometrial surveillance alone (moderate certainty).
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer recurrence compared with endometrial surveillance alone (moderate certainty).
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer‐related death compared with endometrial surveillance alone (moderate certainty).
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
The review found no eligible studies for this question.